Form 4 Filing for Derek J. Maetzold

Derek J. Maetzold, President & CEO of CASTLE BIOSCIENCES INC (CSTL), reported several transactions on May 20th and 21st, 2026. These transactions, executed under a Rule 10b5-1 plan, involved the acquisition of common stock at $2.39 per share and the sale of common stock at prices ranging from $20.002 to $20.196. Specifically, on May 20th, Maetzold acquired 130 shares and sold 130 shares, with further sales of 322, 273, 66, 66, 66, and 66 shares from various trusts. On May 21st, he acquired 420 shares and sold 420 shares, along with sales of 1035, 880, 212, 212, 212, and 212 shares from trusts. The filing also notes indirect holdings in several trusts, including DJM Grantor Retained Annuity Trust No. 5, 6, and 7, and various Maetzold family trusts. Derivative transactions included the exercise of stock options.